CD8A and disease arising from reactivation of latent virus: Therefore, these CD8+ T cell types might present the advantages of A1D4/MTO over BCG to protect against latent infection, providing indirect evidence to support the popular strategy of BCG priming and heterologous boosting with A1D4/MTO in future studies in order to remedy CD8+ T-cell responses after BCG vaccination and limit infection and progression to active TB.